Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference55 articles.
1. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.
2. Zago G, Muller M, van den Heuvel M, Baas P. New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics. 2016;10:103–17. https://doi.org/10.2147/btt.S87878.
3. Marrone KA, Naidoo J, Brahmer JR. Immunotherapy for lung cancer: no longer an abstract concept. Semin Respir Crit Care Med. 2016;37(5):771–82. https://doi.org/10.1055/s-0036-1592298.
4. Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388(10048):1012–24. https://doi.org/10.1016/s0140-6736(16)31473-8.
5. Xiong W, Zhao Y, Du H, Guo X. Current status of immune checkpoint inhibitor immunotherapy for lung cancer. Front Oncol. 2021. https://doi.org/10.3389/fonc.2021.704336.